Member Info for Steg

Good question jamtart1 no idea though, I would have thought that mash human trials would be very expensive and they would want a partner for that ideally but failing that if they had enough money to go to stahpge 1 or 2 from dog cash that might suit as initial success would mean as little money as possible is left on the table. If initial efficacy is proven the fireworks I believe would come very ay

Uickly. Short term I am just hoping the clock results are good and a mega deal is landed with animal pharma. If the deal happens and it’s good then I think we could see a rerate in the so

Genflow Biosciences is currently conducting a strategic analysis of multiple new indications that could be launched under their broad SIRT6 patent portfolio. Their primary patents cover the centenarian variant of the SIRT6 gene, its composition of matter, and specific methods of use for treating age-related diseases.

Proactive financial news

Proactive financial news

+3

Based on their intellectual property (IP) and recent corporate updates, Genflow could launch programs in the following high-value areas:

Cardiovascular Disease (CVD):

Research indicates that SIRT6 deficiency causes inflammation and cell damage leading to atherosclerosis and heart failure.

Genflow's patents for SIRT6 variants specifically list cardiovascular disorders as a key potential application.

Neurodegenerative Diseases:

The SIRT6 gene is linked to DNA repair and genomic stability, which are critical in age-related cognitive decline.

The company has noted that its longevity gene therapy platform provides a "broad-based solution" to multiple age-related diseases, which naturally includes neurodegenerative conditions.

Ophthalmology (Beyond Current Focus):

While Genflow has already launched an initiative for glaucoma and corneal disease, the patent covers broader ocular applications.

High-value expansions could include age-related macular degeneration (AMD), leveraging their existing non-viral vector delivery system.

Sarcopenia and Muscle Atrophy:

The company is already refining a muscle-loss treatment (GF-1005) using dual-gene technology.

This program could expand into broader frailty syndromes, which represent a significant unmet medical need in aging populations.

Metabolic Conditions (Beyond MASH):

The SIRT6 platform has been identified as relevant for various metabolic conditions, including Type 2 Diabetes, due to its role in glucose metabolism and insulin sensitivity.

Gene Editing Applications:

Genflow holds a provisional patent for editing the SIRT6 gene itself (rather than just delivering a new copy).

This could lead to high-value CRISPR-based programs aimed at permanently enhancing SIRT6 function in patients.

The Genflow Biosciences (LSE:GENF) patent portfolio is designed to create a "defensive barrier" that makes them an attractive partner for large pharmaceutical companies looking to enter the longevity space

Https://longevity.technology/news/fda-rewrites-drug-approval-rules-and-longevity-stands-to-gain/

Hi money sounds good all very exciting. If you don’t mind me asking where did you find the information out? I wonder what price the warrants are at. Also now think the methylation clock results will be good, or AI does lol, so in the event of a full program buyout what do you think it’s worth?

Could easily be I would say between me and my family we have 1.5% as we have been following for 2 years, love the story and keep thing that’s us off but now I do think dog clock result funding secured and out the way, fair chance if results are good it will trigger one or more formal offers, due diligence for this kind of deal is normally an average of 3 month however I suspect parties who sign the nda will be well along the track. Tbh I am hoping we see a bit of a bidding war or dog and mash deal at the same time

Thought below was interesting, yes they are attending conference and have already made move to add to thier MASH portfolio, courtesy of AI search below

Yes, Madrigal Pharmaceuticals is actively looking to expand its MASH (metabolic dysfunction-associated steatohepatitis) portfolio beyond its already approved drug, Rezdiffra (resmetirom).

Madrigal's expansion strategy focuses on developing potential combination therapies, as MASH is a complex disease that requires multiple treatment approaches.

Key components of their expanded pipeline include:

Ervogastat: In January 2026, Madrigal entered into an exclusive global license agreement with Pfizer to acquire ervogastat, a Phase 2 oral DGAT-2 inhibitor. This drug works on a different, complementary pathway to Rezdiffra, and Madrigal plans to conduct studies to test the two treatments in combination.

Oral GLP-1 Receptor Agonist: Madrigal also holds worldwide rights to an oral GLP-1 agonist called SYH2086, licensed from CSPC Pharmaceutical, with the goal of creating a best-in-class oral combination therapy.

Additional Early-Stage Assets: The agreement with Pfizer for ervogastat also included rights to two other early-stage MASH pipeline assets.

Madrigal's CEO, Bill Sibold, has stated that the company is committed to "building the industry-leading pipeline that will shape the future of MASH care" and believes combination therapies are the next wave of innovation in the field.

USA joint listing possibly on the way 👍👍

Great research as always Money.

Just need the FDA to reclassify ageing as a disease and we are off like a rocket

Will make longevity companies the hottest companies in the world imho

Might come sooner than we expect as the dialogue is heating up and the fda are going to be under pressure to lead the way

Fingers crossed but this feels like a very exciting place to be

The financial report is on the website under investors section and shareholders documents 👍

That’s 6 then! All feels rather exciting on no news and we are moving in the right direction. So many potential catalysts that could cause this share to explode. I would rather be out than in that’s for sure 👍